Synairgen CEO lays out plans for 2023 and beyond

(4:37)

Synairgen CEO on funding critical Phase 2 trial for SNG001

(3:7)

In Conversation with Richard Marsden, CEO, Synairgen

(11:29)

Synairgen Seeks FDA, EMA Engagement on Covid-19 Drug

(3:5)

Synairgen provides update on progress during 2023

(3:17)

Synairgen’s Covid treatment can still have a role in severe cases explains CEO Marsden

(8:29)

Richard Marsden, CEO - Synairgen (SNG) at SHARES Investor Evenings

(30:34)

Expect better performance from smaller AI companies in 2025, says Deepwater's Gene Munster

(6:5)

Sovereign Metals confirms Kasiya natural rutile deposit is “the largest ever discovered”

(4:45)

Cramer: This biotech stock could be worth over $100 billion on an FDA approval

(5:19)

China's institutional investors foresee low economic growth, hence snapping up government bonds: CIO

(4:5)

5 Herbs for Lung Health, Clearing Mucus, COPD, and Killing Viruses

(8:3)

Next generation CRISPR screens based on single-cell transcriptomics | Tilmann Buerckstuemmer

(24:51)

Advanced Therapeutics Panel @ Sachs_EHTF

(58:36)

Novartis CEO: Expect continued growth in 2023

(6:12)

Year-end video message 2020 from CEO Stephan Sturm

(5:46)

Amplifying Scientific Innovation with Mr. Tan Rasab, CEO, Sigenex

(39:35)

Synairgen’s CEO Richard Marsden details the company’s plans following 2022 interim results

(5:28)

AI, vaccine distrust, \u0026 the future of healthcare: Novartis CEO

(24:1econd)

Synairgen PLC's Richard Marsden hails positive results from study on COVID-19 patients

(7:15)

Synairgen looking beyond COVID in fight against respiratory illness

(3:55)

BIO-Europe® 2018: Synairgen developing COPD treatment to hold off further viral damage

(9:10)

Synairgen on backing for pivotal clinical trial

(24)

Synairgen makes progress in H1 as it moves towards phase II trial of lead asset

(4:18)

Synairgen says its drug well tolerated in phase II trial

(5:27)

FinnCap Short Interview with Richard Marsden, CEO, Synairgen

(11:28)

Synairgen awaits Covid-19 treatment clinical test results in July

(19:36)

Synairgen: Richard Marsden presents updates on all three Covid-19 treatment trials

(12:47)

Synairgen PLC pleased with further positive data from lead COPD drug

(5:51)